Pharma

Jun 20 2018

Persuasive Selling and Marketing, The 7 Triggers to Yes, raptor pharma.#Raptor #pharma

HACK YOUR CUSTOMER S BRAIN For leaders, marketers, salespeople, entrepreneurs – and anyone who wants to make something happen . With the formula developed in Russ Granger’s critically-acclaimed book, certified Trigger training is tactical practice building more persuasive marketing and sales communications using your actual products and services and your real-world customer challenges. Click below to email us Get details on training, consulting, customization, pricing, and more. 855-242-6300 YES IS MORE. Some of the world s largest and smartest companies are using the 7 Triggers system to boost business and profits. Actual reviews from healthcare, technology, engineering, and financial services. …

Jun 20 2018

Information Hospitali – re – L actualit – m – dicale et hospitali – re en ligne, raptor pharma.#Raptor #pharma

raptor pharma Sous l’autoritй du Directeur, le Responsable des R . L’Hфpital Gйrontologique de Chevreuse, йtablisseme . Afin de complйter son йquipe d’animation, l’hфpita . 3 secteurs d?activitйs : Actus santй Dйmographie : mйdecin traitant, un mйtier en perdition ? Les gйnйralistes seraient ils en voie de disparition ? C’est ce que pourrait suggйrer l’atlas 2015 de la dйmographie mйdicale prйsentй, mardi 16 juin 2015 par le Conseil national de l’ordre des mйdecins (CNOM). Tour d’horizon d’une profession vieillissante… Zona : un vaccin enfin disponible. Depuis lundi 15 juin 2015, un nouveau vaccin a fait son apparition sur le comptoir …

Jun 20 2018

Skeptical Raptor – Stalking pseudoscience in the internet jungle, raptor pharma.#Raptor #pharma

Skeptical Raptor Enormous economic value of vaccination – the case is clear The enormous economic value of vaccination – that is, the economic benefits of a vaccine far outweighs the costs – is often overlooked, especially by those who invent some massive conspiracy by Big Pharma to push vaccines. The standard anti-vaccine trope is that vaccines are a gargantuan profit center for pharmaceutical companies. That would be false. In fact, if we are going to endow Big Pharma with immorality and evil motives, they would stop making vaccines and profiting off of the massive illnesses that would ensue. But that …

Mar 15 2018

Elkus Manfredi Architects, raptor pharmaceuticals.#Raptor #pharmaceuticals

raptor pharmaceuticals Civic | Public Las Vegas City Hall Las Vegas, Nevada 309,000 square feet [ Click for PDF ] Charles/MGH MBTA Station Higher Education Rutgers University Honors College Residence Hall New Brunswick, New Jersey 170,000 square feet square feet University of Massachusetts Emerson College Franklin & Marshall Harvard University The Ohio State University Emerson College Tufte Performance and Production Center Duke University Hospitality | Dining The Verb Hotel Boston, Massachusetts InterContinental Boston The Peninsula Chicago Happy’s Bar + Kitchen Not Your Average Joe’s Tico Via Matta Rock Center Cafe Harvest International Via Montejo Centro Comercial Merida, Mexico [ Click …

Mar 9 2018

Top 10 POISONS most Americans eat or drink EVERY day –, raptor pharma.#Raptor #pharma

Top 10 POISONS most Americans eat or drink EVERY day Wednesday, October 25, 2017 by: S.D. Wells (Natural News) If you accidentally sprayed roach killer or weed killer on your fruit, you would probably rush to wash it off, knowing it would make you sick if you ate it, now or later (in fact you would probably discard the produce entirely). If you put poisonous rat baits or pest-killing food pellets under your home, you would certainly make sure your dog or cat couldn t get to them, knowing what would happen if they did. Heck, that s just common …

Mar 9 2018

Biotech Industry, Biotech News, Biotechnology Articles, raptor pharma.#Raptor #pharma

raptor pharma Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms. Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing. Cytokinetics cans lead drug after phase 3 ALS wipeout Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial. Step Pharma bags cash for CTPS1 autoimmune R D drive …

Mar 9 2018

Ciclos Completos > Ciclos de Definiciуn y Rayado en Esteroides Anabolicos Ciclos Suplementos Deportivos Alimenticios, Mesoterapia, Ciclos de Esteroides, raptor pharma.#Raptor #pharma

raptor pharma Excelente ciclo definiciуn y rayado para un usuario principiante con la mejor Calidad Excelente ciclo de definiciуn y rayado para avanzados con la mбs alta calidad. Excelente ciclo para definiciуn y masa muscular Este ciclo es perfecto para aquellas mujeres que quieren ganar un poco de masa muscular y definiciуn Excelente ciclo de definiciуn y rayado para un intermedio Excelente combinacion para marcar el musculo y masa magra. Este ciclo es ideal para definiciуn o masa magra. Provee ganancias cualitativas mбs no cuantitativas. Excelente ciclo de definiciуn y rayado para nivel basico-intermedio Excelente ciclo para definiciуn y rayado …

Jan 23 2018

Information Hospitali – re – L actualit – m – dicale et hospitali – re en ligne, raptor pharmaceuticals.#Raptor #pharmaceuticals

raptor pharmaceuticals Sous l’autoritй du Directeur, le Responsable des R . L’Hфpital Gйrontologique de Chevreuse, йtablisseme . Afin de complйter son йquipe d’animation, l’hфpita . 3 secteurs d?activitйs : Actus santй Dйmographie : mйdecin traitant, un mйtier en perdition ? Les gйnйralistes seraient ils en voie de disparition ? C’est ce que pourrait suggйrer l’atlas 2015 de la dйmographie mйdicale prйsentй, mardi 16 juin 2015 par le Conseil national de l’ordre des mйdecins (CNOM). Tour d’horizon d’une profession vieillissante… Zona : un vaccin enfin disponible. Depuis lundi 15 juin 2015, un nouveau vaccin a fait son apparition sur le comptoir …

Jan 23 2018

Suplementos Alimenticios en Esteroides Anabolicos Ciclos Suplementos Deportivos Alimenticios, Mesoterapia, Ciclos de Esteroides, raptor pharmaceuticals.#Raptor #pharmaceuticals

raptor pharmaceuticals Los mejores productos para antes de entrenar desde bcaa s hasta Oxidos Nitricos y mas. Las mas importantes Vitaminas A,B,C Antioxidantes, Omega 3, 6, 9 y muchos mas.

Jan 19 2018

Information Hospitali – re – L actualit – m – dicale et hospitali – re en ligne, raptor pharma.#Raptor #pharma

raptor pharma Sous l’autoritй du Directeur, le Responsable des R . L’Hфpital Gйrontologique de Chevreuse, йtablisseme . Afin de complйter son йquipe d’animation, l’hфpita . 3 secteurs d?activitйs : Actus santй Dйmographie : mйdecin traitant, un mйtier en perdition ? Les gйnйralistes seraient ils en voie de disparition ? C’est ce que pourrait suggйrer l’atlas 2015 de la dйmographie mйdicale prйsentй, mardi 16 juin 2015 par le Conseil national de l’ordre des mйdecins (CNOM). Tour d’horizon d’une profession vieillissante… Zona : un vaccin enfin disponible. Depuis lundi 15 juin 2015, un nouveau vaccin a fait son apparition sur le comptoir …

Jan 19 2018

Bad science warning: More than 30, 000 studies may have been compromised by contaminated cell lines used for decades –, raptor pharma.#Raptor #pharma

Bad science warning: More than 30,000 studies may have been compromised by contaminated cell lines used for decades Wednesday, October 18, 2017 by: Isabelle Z. (Natural News) What if everything you thought you knew turned out to be wrong? Books and movies have posed this dramatic question in the past, but now it could become reality as new research casts doubt on the cell samples used for more than 30,000 scientific studies. According to a report out of Radboud University in the Netherlands, 451 cell cultures that were used for thousands of scientific experiments are contaminated, and this could have …

Dec 26 2017

Raptor pharma #pharma #crm

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Dec 26 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #pharma.com

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Dec 26 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #shire #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Dec 2 2017

Raptor Pharmaceutical Corp #generic #pharma

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Dec 2 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #biotechnology #company

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Dec 2 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #glide #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Nov 25 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #pharma #canada

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Nov 15 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #new #pharmaceuticals

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Nov 15 2017

Here s Why Raptor Pharmaceuticals Corp #biotechnology #industry

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

Nov 15 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #luye #pharma

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Nov 6 2017

Raptor pharma #vifor #pharma

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Nov 6 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #rusan #pharma

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Sep 8 2017

Here s Why Raptor Pharmaceuticals Corp #marketing #pharmaceuticals

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

Aug 17 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #astellas #pharma #inc

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Aug 17 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #pharmaceutical #industry #market #share

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Aug 9 2017

Raptor Pharmaceutical Corp #diamond #pharma

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Aug 9 2017

Here s Why Raptor Pharmaceuticals Corp #pharma #iq

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

Aug 9 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #verona #pharma

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Aug 2 2017

Raptor Pharmaceutical Corp #generic #drug #company

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Aug 2 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #alliance #pharma

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Aug 2 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #pharmaceutical #representative

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Jul 25 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #biggest #pharmaceutical #companies

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Jul 25 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #generic #pharma #companies

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Jul 10 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #sun #pharma #sikkim

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Jul 5 2017

Raptor pharma #helix #pharma

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Jun 15 2017

Raptor pharma #shionogi #pharma #inc

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

May 16 2017

Here s Why Raptor Pharmaceuticals Corp #industry #pharmacy

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

May 16 2017

Raptor Pharmaceutical Corp #cafe #pharma #merck

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

May 16 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #marksans #pharma

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

May 16 2017

Raptor pharma #pharmaceutical #companies #in #orange #county

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Apr 21 2017

Raptor pharma #health #it #companies

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Apr 21 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #d #pharma

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Apr 21 2017

Raptor Pharmaceutical Corp #cafe #pharma #boards

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Apr 12 2017

Here s Why Raptor Pharmaceuticals Corp #pharmaceutical #recruiters

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

Apr 3 2017

Raptor Pharmaceutical Corp #pharma #projects

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Apr 3 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #biotechnology #jobs

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Mar 23 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #pharmaceutical #industries

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Mar 20 2017

Here s Why Raptor Pharmaceuticals Corp #intas #pharma

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …

Feb 2 2017

Raptor pharma #millenium #pharma

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …